9-month temporary modelling scientist position at Novo Nordisk A/S

Do you want to conduct PK/PD and exposure-response analyses to support the development of new drugs at Novo Nordisk in a 9-month temporary position? About the department The Quantitative Clinical Pharmacology department supports the entire Novo Nordisk development portfolio with model-based analyses from first in human studies to registration. You will be part of a diverse team of dedicated modelling and clinical pharmacology scientists in our R&D Global Development organisation. The Job As Modelling Scientist you will have an important role in the development of new drugs at Novo Nordisk, taking part in designing, analysing, interpreting, communicating and reporting quantitative clinical pharmacology information (e.g. population PK/PD and exposure-response analyses) at all stages of clinical drug development. You will be part of multidisciplinary project teams where you will be responsible for developing modelling analysis plans for the project and follow them to completion. Qualifications You hold a university degree in a relevant area (Statistics, Engineering, Pharmacy or other), preferably with a supplementary Ph.D. You are fluent in English both orally and written. You have a strong background in pharmacokinetics, statistics and/or quantitative clinical pharmacology analyses and have hands-on experience using S-PLUS/R and/or NONMEM. You are innovative with a high degree of independence, result and quality oriented, and thrive in a continuously changing environment with tight deadlines. You appreciate an informal atmosphere and act as a dedicated team player. As your colleagues will have different academic backgrounds, good presentation, communication and negotiation skills are essential. Contact For further information, please contact Christoffer Wenzel Tornøe at +45 3075 8193. Deadline 18 December 2013 To apply http://novonordisk.com/careers/job_section/current_jobs.asp?jobid=17295BR&lCountry= Best regards Christoffer ____________________________________ Christoffer Wenzel Tornøe, Ph.D. Director Quantitative Clinical Pharmacology Novo Nordisk A/S Vandtårnsvej 108-110 DK-2860 Søborg Denmark +45 3075 8193 (direct) +45 3075 8193 (mobile) [email protected] Changing how we treat diabetes Because diabetes is as varied as people's lifestyles, Novo Nordisk has developed the broadest range of insulin products on the market. Click here to read http://www.novonordisk.com/about_us/changing-diabetes-activities/insulin-and-devices.asp This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you.